Unrelated cord blood transplant demonstrated efficacy in patients with blood cancer after microcystic adnexal carcinoma.

The ultra-sensitive detection of MRD in AML is a critical tool for advancing clinical research in AML. NGS-based AML MRD is being more widely adopted in drug development and studies aiming to improve ...

The ultra-sensitive detection of MRD in AML is a critical tool for advancing clinical research in AML. NGS-based AML MRD is being more widely adopted in drug development and studies aiming to improve ...

MRD negativity in MM patients correlates with improved survival, suggesting its potential as a surrogate marker for survival outcomes. Novel therapeutics complicate the assessment of PFS and OS ...

TC BioPharm's Phase 2B trial of TCB008 in AML progresses as the first Cohort B patient completes dosing. Enrollment continues, with data expected in 2025.

PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced ...

Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment Continues Promising Data, including a 59% Stable ...